{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ03027",
      "entity_text" : "Risk",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:6041",
      "entity_text" : "duration",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "More recently, the Acute medically Ill venous thromboembolism Prevention with EXtended duration betrixaban (APEX) XREF_BIBR and Medically ill patient Assessment of Rivaroxaban vs. placebo IN reducing post-discharge venous thrombo-Embolism Risk (MARINER) studies XREF_BIBR, XREF_BIBR included baseline D dimer levels in their evaluations of duration of pharmacological prophylaxis after discharge (35 to 42 days, and 45 days, respectively).",
  "reading_complete" : "2020-08-04T13:57:28Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T13:56:13Z",
  "trigger" : "reducing",
  "evidence" : [ "reducing post-discharge venous thrombo-Embolism Risk (MARINER) studies XREF_BIBR \n , \n XREF_BIBR  included baseline D dimer levels in their evaluations of duration" ],
  "pmc_id" : "6636813",
  "score" : 0
}